Effect_NN of_IN the_DT Echinocandin_NP Caspofungin_NP on_IN Expression_NP of_IN Candida_NP albicans_NP Secretory_NP Aspartyl_NP Proteinases_NPS and_CC Phospholipase_NP In_IN Vitro_NP Although_IN the_DT echinocandin_NN caspofungin_NN primarily_RB inhibits_VBZ the_DT synthesis_NN of_IN cell_NN wall_NN 1,3-beta-d-glucan_JJ ,_, its_PP$ fungicidal_JJ activity_NN could_MD also_RB potentially_RB perturb_VB the_DT expression_NN of_IN virulence_NN factors_NNS involved_VBN in_IN the_DT ability_NN of_IN Candida_NP albicans_NNS to_TO cause_VB infection_NN ._SENT Expression_NN of_IN the_DT C._NP albicans_NNS secretory_JJ aspartyl_NN proteinase_NN (_( SAP_NP )_) and_CC phospholipase_NN B_NP (_( PLB_NP )_) virulence_NN genes_NNS was_VBD determined_VBN by_IN reverse_JJ transcription-PCR_NN after_IN the_DT addition_NN of_IN caspofungin_NN to_TO cells_NNS grown_VBN for_IN 15_CD h_NN in_IN Sabouraud_NP dextrose_NN broth_NN ._SENT In_IN cells_NNS that_WDT remained_VBD viable_JJ ,_, expression_NN of_IN SAP1_NP to_TO SAP3_NP ,_, SAP7_JJ to_TO SAP9_NP ,_, and_CC PLB1_NP was_VBD unaltered_VBN after_IN exposure_NN to_TO fungicidal_JJ concentrations_NNS (_( 4_CD to_TO 16_CD mug/ml_NN )_) of_IN caspofungin_NN over_IN a_DT period_NN of_IN 7_CD h._NN However_RB ,_, expression_NN of_IN SAP5_NP increased_VBD steadily_RB beginning_VBG 1_CD h_NN after_IN exposure_NN to_TO caspofungin_NN ._SENT These_DT results_NNS indicate_VBP that_IN caspofungin_NN is_VBZ rapidly_RB fungicidal_JJ against_IN C._NP albicans_NNS ,_, before_IN any_DT suppression_NN of_IN SAP_NP or_CC PLB1_NP gene_NN expression_NN can_MD occur_VB ._SENT The_DT cyclic_JJ lipopeptide_NN pneumocandins_NNS and_CC echinocandins_NNS and_CC the_DT glycolipid_JJ papulacandins_NNS are_VBP members_NNS of_IN a_DT new_JJ class_NN of_IN antifungal_JJ agents_NNS which_WDT exert_VBP their_PP$ activity_NN by_IN noncompetitive_JJ inhibition_NN of_IN fungal_JJ 1,3-beta-d-glucan_JJ synthase_NN ._SENT This_DT enzyme_NN is_VBZ essential_JJ for_IN the_DT synthesis_NN of_IN cell_NN wall_NN glucan_NN which_WDT provides_VBZ structural_JJ integrity_NN and_CC osmotic_JJ stability_NN for_IN fungi_NNS but_CC is_VBZ not_RB found_VBN in_IN cells_NNS from_IN higher_JJR eukaryotes_NNS including_VBG humans_NNS ._SENT Disruption_NN of_IN cell_NN wall_NN structure_NN by_IN inhibition_NN of_IN glucan_JJ synthesis_NN results_NNS in_IN osmotic_JJ instability_NN and_CC lysis_NN of_IN the_DT fungal_JJ cell_NN ._SENT Caspofungin_NP (_( MK-0991_NP )_) is_VBZ a_DT water-soluble_JJ semisynthetic_JJ amine_NN derivative_NN of_IN the_DT natural_JJ product_NN pneumocandin_NP Bo_NP ,_, which_WDT in_IN turn_NN is_VBZ a_DT fermentation_NN product_NN derived_VBN from_IN the_DT fungus_NN Glarea_NN lozoyensis_NN ._SENT Caspofungin_NP was_VBD developed_VBN as_IN a_DT potential_JJ antifungal_NN and_CC anti-Pneumocystis_NN agent_NN ._SENT In_IN vitro_NP ,_, caspofungin_NN is_VBZ fungicidal_JJ against_IN Candida_NP species_NNS ,_, including_VBG azole-resistant_JJ species_NNS ,_, and_CC is_VBZ fungistatic_JJ against_IN Aspergillus_NP species_NNS ._SENT However_RB ,_, it_PP is_VBZ inactive_JJ against_IN Fusarium_NP ,_, Rhizopus_NP ,_, Trichosporon_NP ,_, and_CC Cryptococcus_NP neoformans_NNS ._SENT In_IN addition_NN to_TO prolonging_VBG survival_NN in_IN mouse_NN models_NNS of_IN disseminated_VBN candidiasis_NN and_CC aspergillosis_NN ,_, caspofungin_NN has_VBZ recently_RB shown_VBN promising_JJ clinical_JJ activity_NN for_IN the_DT treatment_NN of_IN life-threatening_JJ infections_NNS caused_VBN by_IN Candida_NP and_CC Aspergillus_NP species_NNS (_( ;_: J._NP Maertens_NP ,_, I._NP Raad_NP ,_, C._NP A._NP Sable_NP ,_, A._NP Ngai_NP ,_, R._NP Berman_NP ,_, T._NP F._NP Patterson_NP ,_, D._NP Denning_NP ,_, and_CC T._NP Walsh_NP ,_, Abstr_NP ._SENT 40th_JJ Intersci_NP ._SENT Conf_NP ._SENT Antimicrob_NN ._SENT Agents_NPS Chemother_NP ._SENT ,_, abstr_NN ._SENT 1103_CD ,_, 2000_CD ;_: A._NP Villanueva_NP ,_, E._NP Gotuzzo_NP ,_, E._NP Arathoon_NP ,_, L._NP M._NP Noriega_NP ,_, N._NP Kartsonis_NP ,_, R._NP Lupinacci_NP ,_, J._NP Smietana_NP ,_, R._NP S._NP Berman_NP ,_, M._NP J._NP Dinubile_NP ,_, and_CC C._NP A._NP Sable_NP ,_, Abstr_NP ._SENT 41st_NP Intersci_NP ._SENT Conf_NP ._SENT Antimicrob_NN ._SENT Agents_NPS Chemother_NP ._SENT ,_, abstr_NP ._SENT J-675_NP ,_, 2001_CD )_) ._SENT Because_IN caspofungin_NN is_VBZ fungicidal_JJ ,_, it_PP could_MD potentially_RB affect_VB a_DT diversity_NN of_IN cellular_JJ processes_NNS which_WDT contribute_VBP to_TO the_DT ability_NN of_IN Candida_NP albicans_NNS to_TO cause_VB infection_NN ._SENT The_DT primary_JJ mechanism_NN of_IN action_NN of_IN pneumocandins_NNS and_CC echinocandins_NNS is_VBZ inhibition_NN of_IN synthesis_NN of_IN cell_NN wall_NN 1,3-beta-d-glucan_JJ ,_, and_CC these_DT compounds_NNS do_VBP not_RB inhibit_VB other_JJ C._NP albicans_NNS membrane-bound_JJ enzymes_NNS ,_, such_JJ as_IN chitin_NN synthase_NN or_CC serine_NN palmitoyltransferase_NN ._SENT However_RB ,_, echinocandin_NN antimycotics_NNS inhibit_VBP the_DT incorporation_NN of_IN glucan-associated_JJ enolase_NN into_IN the_DT growing_VBG cell_NN wall_NN of_IN C._NP albicans_NNS ._SENT In_IN addition_NN ,_, although_IN the_DT synthesis_NN of_IN C._NP albicans_NP RNA_NP is_VBZ only_RB modestly_RB inhibited_VBN at_IN the_DT MIC_NN of_IN the_DT pneumocandin_NP L-733,560_NP ,_, a_DT close_JJ analogue_NN of_IN caspofungin_NN ,_, marked_JJ inhibition_NN occurs_VBZ at_IN 250_CD times_NNS the_DT MIC_NN ._SENT Fungal_JJ virulence_NN factors_NNS are_VBP attracting_VBG attention_NN as_IN potential_JJ targets_NNS for_IN drug_NN development_NN ._SENT C._NP albicans_NNS secretory_JJ aspartyl_NN proteinases_NNS (_( Saps_NP )_) ,_, under_IN the_DT control_NN of_IN a_DT multigene_JJ family_NN (_( SAP1_JJ to_TO SAP9_NP )_) expressing_VBG distinct_JJ isoenzymes_NNS which_WDT are_VBP regulated_VBN differentially_RB at_IN the_DT mRNA_NN level_NN in_IN vitro_NN and_CC in_IN vivo_RB ,_, are_VBP implicated_VBN in_IN the_DT breakdown_NN of_IN several_JJ host_NN substrates_NNS ._SENT There_EX is_VBZ evidence_NN that_IN phospholipase_NN B_NN expressed_VBD by_IN at_IN least_JJS two_CD genes_NNS (_( PLB1_NP and_CC PLB2_NP )_) also_RB contributes_VBZ to_TO the_DT pathogenesis_NN of_IN candidiasis_NN by_IN the_DT degradation_NN of_IN host_NN tissues_NNS ._SENT The_DT potential_JJ impact_NN of_IN antifungal_JJ therapies_NNS on_IN expression_NN of_IN C._NP albicans_NNS virulence_NN factors_NNS is_VBZ exemplified_VBN by_IN the_DT enhanced_JJ production_NN of_IN Sap_NP by_IN azole-resistant_JJ C._NP albicans_NNS isolates_VBZ from_IN a_DT patient_NN infected_VBN with_IN human_JJ immunodeficiency_NN virus_NN after_IN growth_NN in_IN subinhibitory_JJ concentrations_NNS of_IN fluconazole_NN ._SENT In_IN the_DT present_JJ study_NN ,_, we_PP sought_VBD to_TO determine_VB whether_IN caspofungin_NN could_MD potentially_RB exert_VB added_JJ anticandidal_JJ activity_NN by_IN inhibiting_VBG the_DT expression_NN of_IN C._NP albicans_NP SAPs_NP and_CC PLB1_NP ,_, as_IN a_DT consequence_NN of_IN nonspecific_JJ effects_NNS on_IN transcription_NN ._SENT Sap-_NN and_CC phospholipase-producing_NN C._NP albicans_NP LAM-1_NP (_( serotype_NP A_NP )_) was_VBD originally_RB isolated_VBN from_IN the_DT blood_NN of_IN a_DT patient_NN with_IN systemic_JJ candidiasis_NN ._SENT The_DT isolate_NN was_VBD stored_VBN at_IN -80C_NN in_IN a_DT solution_NN containing_VBG 65_CD %_NN (_( vol/vol_NN )_) glycerol_NN ,_, 10_CD mM_NP Tris_NP (_( pH_NN 7.5_CD )_) ,_, and_CC 10_CD mM_NP MgCl2_NP ._SENT Prior_RB to_TO use_VB ,_, Candida_NP was_VBD cultured_VBN at_IN 37C_JJ on_IN Sabouraud_NP dextrose_NN agar_NN (_( SDA_NP )_) (_( Becton_NP Dickinson_NP and_CC Company_NP ,_, Cockeysville_NP ,_, Md._NP )_) ._SENT The_DT susceptibility_NN of_IN C._NP albicans_NNS strain_VBP LAM-1_NP to_TO antifungal_JJ agents_NNS was_VBD determined_VBN by_IN the_DT broth_NN microdilution_NN version_NN of_IN the_DT M27-A_NP method_NN defined_VBN by_IN the_DT National_NP Committee_NP for_IN Clinical_NP Laboratory_NP Standards_NPS ._SENT The_DT method_NN was_VBD performed_VBN in_IN RPMI_NP 1640_CD medium_NN (_( Gibco_NP BRL_NP ,_, Gaithersburg_NP ,_, Md._NP )_) buffered_VBD to_TO pH_NN 7.0_CD with_IN 0.165_CD M_NP morpholinepropanesulfonic_JJ acid_NN (_( MOPS_NP )_) buffer_NN (_( MOPS-buffered_NP RPMI_NP ;_: ICN_NP Biochemicals_NP ,_, Cleveland_NP ,_, Ohio_NP )_) with_IN readings_NNS at_IN 48_CD h_NN ,_, except_IN for_IN amphotericin_NP B_NP ,_, which_WDT was_VBD tested_VBN in_IN antibiotic_JJ medium_NN 3_CD and_CC read_VBN after_IN 24_CD h_NN ._SENT The_DT MICs_NP of_IN the_DT azoles_NNS and_CC flucytosine_NN were_VBD defined_VBN as_IN the_DT lowest_JJS concentrations_NNS giving_VBG prominent_JJ growth_NN reduction_NN ._SENT For_IN the_DT other_JJ drugs_NNS ,_, the_DT MIC_NP was_VBD the_DT lowest_JJS drug_NN concentration_NN giving_VBG an_DT optically_RB clear_JJ well_RB ._SENT Candida_NP parapsilosis_NN ATCC_NP 22019_CD and_CC Candida_NP krusei_NP ATCC_NP 6258_CD were_VBD included_VBN as_IN quality_NN control_NN isolates_NNS ._SENT After_IN 48_CD h_NN ,_, 20_CD mul_NN of_IN each_DT clear_JJ well_NN was_VBD plated_VBN on_IN SDA_NP ,_, and_CC the_DT minimum_JJ fungicidal_JJ concentration_NN (_( MFC_NP )_) was_VBD the_DT lowest_JJS concentration_NN giving_VBG no_DT growth_NN (_( >98_JJ %_NN killing_NN )_) ._SENT kill_VB curve_NN procedures_NNS ._SENT :_: Caspofungin_NP (_( MK-0991_NP )_) was_VBD provided_VBN as_IN a_DT pure_JJ white_JJ powder_NN by_IN the_DT Merck_NP Research_NP Laboratories_NPS (_( Rahway_NP ,_, N.J._NP )_) and_CC stored_VBN at_IN -80C_NN ._SENT A_DT stock_NN solution_NN at_IN a_DT concentration_NN of_IN 400_CD mug/ml_NN was_VBD prepared_VBN in_IN sterile_JJ distilled_JJ water_NN for_IN each_DT experiment_NN ._SENT Three_CD to_TO five_CD colonies_NNS of_IN C._NP albicans_NNS grown_VBN for_IN 24_CD to_TO 48_CD h_NN on_IN SDA_NP were_VBD suspended_VBN in_IN 5_CD ml_NN of_IN 0.01_CD M_NP phosphate-buffered_JJ saline_NN (_( pH_NN 7.2_CD )_) ,_, and_CC the_DT cells_NNS were_VBD counted_VBN using_VBG a_DT hemacytometer_NN ._SENT An_DT appropriate_JJ volume_NN of_IN fungal_JJ suspension_NN was_VBD then_RB added_VBN to_TO Erlenmeyer_NP flasks_NNS containing_VBG 70_CD ml_NN of_IN either_DT Sabouraud_NP dextrose_NN broth_NN (_( SDB_NP ;_: Difco_NP Laboratories_NPS ,_, Detroit_NP ,_, Mich._NP )_) or_CC MOPS-buffered_NP RPMI_NP to_TO yield_VB a_DT starting_VBG inoculum_NN of_IN approximately_RB 103_CD CFU/ml_NN ._SENT Caspofungin_NP was_VBD added_VBN to_TO individual_JJ cultures_NNS with_IN resulting_VBG concentrations_NNS ranging_VBG from_IN 0.125_CD to_TO 16_CD mug/ml_NN ,_, either_CC at_IN the_DT start_NN of_IN culture_NN or_CC after_IN 15_CD h_NN of_IN incubation_NN with_IN rotary_JJ agitation_NN at_IN 37C_JJ ._SENT Culture_NN medium_NN without_IN drug_NN served_VBN as_IN a_DT growth_NN control_NN ._SENT At_IN predetermined_VBN time_NN points_NNS ,_, duplicate_JJ 100-mul_NP volumes_NNS were_VBD withdrawn_VBN from_IN each_DT culture_NN and_CC serially_RB diluted_JJ (_( 10-fold_NN )_) ,_, and_CC a_DT 100-mul_NP aliquot_NN from_IN each_DT dilution_NN was_VBD plated_VBN on_IN SDA_NP for_IN determination_NN of_IN CFU_NP ._SENT The_DT results_NNS were_VBD expressed_VBN as_IN the_DT averages_NNS of_IN the_DT duplicate_JJ CFU_NP determinations_NNS ._SENT When_WRB colony_NN counts_NNS were_VBD anticipated_VBN to_TO be_VB less_JJR than_IN 103_CD CFU/ml_NP ,_, duplicate_JJ 0.1-ml_NN aliquots_NNS of_IN the_DT cultures_NNS were_VBD plated_VBN directly_RB on_IN SDA_NP without_IN dilution_NN ._SENT A_DT 1-ml_JJ aliquot_NN of_IN each_DT culture_NN was_VBD also_RB removed_VBN at_IN the_DT same_JJ time_NN points_NNS and_CC centrifuged_VBN ,_, and_CC the_DT pellet_NN was_VBD immediately_RB frozen_VBN at_IN -80C_NN for_IN analysis_NN of_IN C._NP albicans_NP SAP_NP and_CC PLB1_NP gene_NN expression_NN ._SENT PCR_NP ._SENT :_: Isolation_NN of_IN RNA_NP from_IN the_DT pelleted_VBN cells_NNS and_CC reverse_JJ transcription-PCR_NN (_( RT-PCR_NP )_) were_VBD performed_VBN as_IN previously_RB described_VBN ._SENT In_IN order_NN to_TO assess_VB gene_NN expression_NN by_IN the_DT portion_NN of_IN C._NP albicans_NNS which_WDT remained_VBD viable_JJ during_IN the_DT time-kill_NN experiments_NNS ,_, RT-PCR_NP for_IN each_DT gene_NN and_CC time_NN point_NN was_VBD conducted_VBN using_VBG an_DT amount_NN of_IN RNA_NP originating_VBG from_IN 1,400_CD CFU_NP of_IN C._NP albicans_NNS ._SENT For_IN the_DT detection_NN of_IN gene_NN expression_NN ,_, individual_JJ digoxigenin-labeled_JJ probes_NNS were_VBD used_VBN to_TO specifically_RB detect_VB each_DT of_IN the_DT RT-PCR_NP products_NNS by_IN Southern_NP blotting_VBG ._SENT Positive_JJ controls_NNS for_IN expression_NN of_IN each_DT of_IN the_DT individual_JJ SAP_NP and_CC PLB1_NP genes_NNS were_VBD included_VBN in_IN the_DT RT-PCR_NP assay_NN ,_, using_VBG RNA_NP from_IN C._NP albicans_NP LAM-1_NP grown_VBN in_IN vitro_NN under_IN conditions_NNS known_VBN to_TO induce_VB their_PP$ expression_NN ._SENT The_DT EFB1_NP gene_NN was_VBD amplified_VBN as_IN a_DT positive_JJ mRNA_NN control_NN and_CC to_TO detect_VB any_DT contaminating_VBG genomic_JJ DNA_NN by_IN the_DT presence_NN of_IN a_DT 365-bp_JJ intron_NN ._SENT A_DT negative_JJ control_NN for_IN expression_NN of_IN each_DT gene_NN was_VBD obtained_VBN by_IN omitting_VBG the_DT RNA_NP in_IN the_DT RT-PCR_NP assay_NN ._SENT The_DT MICs_NP for_IN C.albicans_NP LAM-1_NP were_VBD typical_JJ of_IN those_DT for_IN other_JJ C.albicans_NP isolates_NNS (_( flucytosine_NP ,_, 0.125_CD mug/ml_NN ;_: amphotericin_NP B_NP ,_, 1_CD mug/ml_NN ;_: fluconazole_NN ,_, 0.25_CD mug/ml_NN ;_: itraconazole_NN ,_, 0.125_CD mug/ml_NN ;_: posaconazole_NN ,_, 0.031_CD mug/ml_NN ;_: voriconazole_NN ,_, 0.031_CD mug/ml_NN ;_: caspofungin_NP ,_, 1_CD mug/ml_NN ;_: micafungin_NN [_SYM FK-463_NP ]_SYM ,_, 0.031_CD mug/ml_NN ;_: and_CC anidulafungin_NNS [_SYM LY-303366_NP ]_SYM ,_, 0.031_CD mug/ml_NN )_) ._SENT This_DT strain_NN was_VBD thus_RB susceptible_JJ to_TO all_DT classes_NNS of_IN antifungal_JJ agents_NNS tested_VBD ,_, including_VBG the_DT echinocandins_NNS ._SENT The_DT MFC_NP for_IN caspofungin_NN (_( 1_CD mug/ml_NN )_) was_VBD equivalent_JJ to_TO the_DT MIC_NN ,_, demonstrating_VBG fungicidal_JJ activity_NN against_IN C._NP albicans_NNS and_CC in_IN agreement_NN with_IN reported_VBN in_IN vitro_NN susceptibility_NN data_NNS of_IN C._NP albicans_NNS to_TO this_DT antifungal_NN ._SENT When_WRB caspofungin_NN was_VBD added_VBN at_IN concentrations_NNS (_( 0.125_CD to_TO 1_CD mug/ml_NN )_) at_IN or_CC below_IN the_DT MIC_NN to_TO late-log-phase_JJ C._NP albicans_NNS grown_VBN in_IN SDB_NP for_IN 15_CD h_NN ,_, the_DT apparent_JJ rate_NN of_IN reduction_NN of_IN the_DT number_NN of_IN CFU_NP per_IN milliliter_NN was_VBD unexpectedly_RB inversely_RB proportional_JJ to_TO the_DT drug_NN concentration_NN ._SENT This_DT effect_NN was_VBD correlated_VBN with_IN increasing_VBG macroscopic_JJ and_CC microscopic_JJ clumping_VBG of_IN C._NP albicans_NNS cells_NNS as_IN the_DT concentration_NN of_IN caspofungin_NN decreased_VBD ._SENT Interestingly_RB ,_, aggregates_NNS of_IN C._NP albicans_NNS blastoconidia_NNS have_VBP been_VBN previously_RB observed_VBN in_IN an_DT enriched_VBN synthetic_JJ liquid_JJ medium_NN after_IN 4_CD h_NN of_IN treatment_NN with_IN caspofungin_NN ,_, L-733,560_NP ,_, as_RB well_RB as_IN acidic_JJ terpenoid_NN (_( 1_CD ,_, 3)-beta-d-glucan_JJ synthase_NN inhibitors_NNS ,_, at_IN concentrations_NNS at_IN or_CC below_IN the_DT MIC_NP or_CC MFC_NP (_( ;_: M._NP Kurtz_NP ,_, personal_JJ communication_NN )_) ._SENT In_IN another_DT report_NN ,_, however_RB ,_, caspofungin_NN concentrations_NNS below_IN that_DT required_VBN to_TO inhibit_VB 80_CD %_NN of_IN the_DT strains_NNS resulted_VBN in_IN growth_NN curves_NNS similar_JJ to_TO that_DT for_IN the_DT control_NN in_IN the_DT absence_NN of_IN caspofungin_NN for_IN all_DT C._NP albicans_NNS isolates_VBZ tested_VBN and_CC no_DT report_NN of_IN aggregation_NN ._SENT The_DT apparent_JJ enhanced_JJ killing_NN of_IN C._NP albicans_NNS at_IN caspofungin_NN concentrations_NNS below_IN the_DT MIC_NP may_MD have_VB resulted_VBN from_IN the_DT formation_NN of_IN increasingly_RB large_JJ aggregates_NNS ,_, each_DT giving_VBG rise_NN to_TO a_DT single_JJ colony_NN and_CC consequently_RB being_VBG counted_VBN as_IN 1_CD CFU_NP ._SENT Aggregation_NN was_VBD not_RB prevented_VBN by_IN adding_VBG 0.01_CD %_NN (_( wt/vol_NN )_) Tween_NP 20_CD or_CC 0.0025_CD %_NN Tween_NP 80_CD (_( Fisher_NP Scientific_NP ,_, Fair_NP Lawn_NP ,_, N.J._NP )_) to_TO the_DT SDB_NP culture_NN medium_NN (_( data_NNS not_RB shown_VBN )_) ._SENT In_IN addition_NN ,_, time-kill_NN curves_NNS constructed_VBN by_IN a_DT proposed_VBN standardized_JJ method_NN in_IN RPM1_NP 1640_CD buffered_VBN with_IN MOPS_NP also_RB resulted_VBD in_IN aggregation_NN at_IN values_NNS at_IN or_CC below_IN the_DT MIC_NP and_CC in_IN a_DT rate_NN of_IN killing_VBG comparable_JJ to_TO that_DT in_IN SDB_NP at_IN concentrations_NNS (_( 4_CD to_TO 16_CD mug/ml_NN )_) above_IN the_DT MIC_NP or_CC MFC_NP (_( data_NN not_RB shown_VBN )_) ._SENT As_IN expected_VBN ,_, these_DT higher_JJR concentrations_NNS of_IN caspofungin_NN (_( 4_CD to_TO 16_CD mug/ml_NN )_) all_RB produced_VBD approximately_RB 90_CD %_NN killing_NN of_IN C._NP albicans_NNS within_IN 7_CD h_NN in_IN SDB_NP medium_NN with_IN no_DT visible_JJ aggregation_NN but_CC abundant_JJ cellular_JJ debris_NN microscopically_RB ._SENT The_DT absence_NN of_IN additional_JJ killing_VBG effect_NN against_IN C._NP albicans_NNS at_IN increasing_VBG concentrations_NNS of_IN caspofungin_NN (_( 4_CD to_TO 16_CD mug/ml_NN )_) has_VBZ been_VBN observed_VBN by_IN other_JJ investigators_NNS ._SENT Taken_VBN together_RB ,_, the_DT results_NNS of_IN the_DT time-kill_NN studies_NNS suggest_VBP that_IN inhibition_NN of_IN synthesis_NN of_IN cell_NN wall_NN glucan_NN by_IN caspofungin_NN primarily_RB alters_VBZ the_DT surface_NN properties_NNS of_IN C._NP albicans_NNS at_IN concentrations_NNS below_IN the_DT MIC_NN ,_, causing_VBG the_DT cells_NNS to_TO aggregate_VB ,_, while_IN killing_VBG at_IN concentrations_NNS above_IN the_DT MIC_NP or_CC MFC_NP disrupts_VBZ the_DT cells_NNS and_CC aggregation_NN is_VBZ thus_RB not_RB observed_VBN ._SENT Interestingly_RB ,_, caspofungin_NN at_IN concentrations_NNS below_IN the_DT MIC_NP induces_VBZ a_DT high-affinity_NN fibronectin_NN receptor_NN that_WDT may_MD promote_VB the_DT adhesive_JJ properties_NNS of_IN C._NP albicans_NP (_( M._NP L._NP Pendrak_NP ,_, T._NP J._NP Walsh_NP ,_, and_CC D._NP D._NP Roberts_NP ,_, Prog_NP ._SENT Abstr_NP ._SENT 6th_JJ ASM_NN Conference_NN on_IN Candida_NP and_CC Candidiasis_NP ,_, abstr_NP ._SENT 124_CD ,_, 2002_CD )_) ._SENT Time-kill_NN curves_NNS were_VBD also_RB constructed_VBN by_IN adding_VBG caspofungin_NN to_TO a_DT smaller_JJR inoculum_NN of_IN C._NP albicans_NNS (_( 103_CD CFU_NP )_) at_IN the_DT start_NN of_IN culture_NN in_IN SDB_NP and_CC quantitating_VBG CFU_NP at_IN determined_VBN time_NN points_NNS over_IN 20_CD h_NN of_IN incubation_NN ._SENT The_DT apparent_JJ reduction_NN in_IN CFU_NP was_VBD again_RB inversely_RB proportional_JJ to_TO the_DT concentration_NN of_IN caspofungin_NN because_IN of_IN aggregation_NN ,_, but_CC at_IN least_JJS 99_CD %_NN killing_NN was_VBD achieved_VBN within_IN 9_CD h_NN at_IN higher_JJR concentrations_NNS ._SENT However_RB ,_, a_DT persistent_JJ fraction_NN of_IN C._NP albicans_NNS was_VBD not_RB killed_VBN ,_, and_CC growth_NN of_IN the_DT fungus_NN quickly_RB resumed_VBD until_IN the_DT end_NN of_IN incubation_NN ._SENT It_PP is_VBZ hypothesized_VBN that_IN this_DT rebound_NN in_IN CFU_NP may_MD be_VB the_DT result_NN of_IN decreased_VBN drug_NN stability_NN under_IN the_DT extended_JJ study_NN conditions_NNS ._SENT Monitoring_VBG of_IN the_DT pH_NN at_IN each_DT time_NN point_NN revealed_VBD pH_NN values_NNS of_IN 5_CD to_TO 5.5_CD ,_, making_VBG it_PP unlikely_JJ that_IN caspofungin_NN was_VBD inactivated_VBN by_IN deviating_VBG from_IN the_DT recommended_JJ pH_NN range_NN of_IN 5_CD to_TO 7_CD (_( Merck_NP Research_NP Laboratories_NPS )_) ._SENT Expression_NN of_IN the_DT SAP1_NP to_TO SAP9_NP and_CC PLB1_JJ genes_NNS of_IN C._NP albicans_NNS was_VBD determined_VBN by_IN RT-PCR_NP after_IN the_DT addition_NN of_IN caspofungin_NN (_( 4_CD to_TO 16_CD mug/ml_NN )_) to_TO cells_NNS grown_VBN for_IN 15_CD h_NN in_IN SDB_NP ._SENT In_IN comparison_NN to_TO a_DT control_NN culture_NN without_IN caspofungin_NN ,_, expression_NN of_IN SAP1_NP to_TO SAP3_NP ,_, SAP7_JJ to_TO SAP9_NP ,_, PLB1_NP ,_, and_CC the_DT EFB1_JJ positive-control_NN gene_NN was_VBD unaltered_VBN at_IN these_DT drug_NN concentrations_NNS over_IN a_DT period_NN of_IN 7_CD h_NN ._SENT Interestingly_RB ,_, however_RB ,_, expression_NN of_IN SAP5_NP increased_VBD steadily_RB beginning_VBG 1_CD h_NN after_IN exposure_NN to_TO these_DT concentrations_NNS of_IN caspofungin_NN ._SENT Although_IN SAP5_NP is_VBZ expressed_VBN in_IN vitro_NN by_IN the_DT hyphal_JJ form_NN of_IN C._NP albicans_NNS at_IN neutral_JJ pH_NN ,_, expression_NN has_VBZ been_VBN found_VBN using_VBG in_IN vivo_JJ expression_NN technology_NN in_IN a_DT murine_JJ model_NN of_IN esophageal_JJ candidiasis_NN when_WRB only_JJ blastoconidia_NNS are_VBP observed_VBN ._SENT Although_IN regulation_NN of_IN expression_NN of_IN the_DT SAP_NP genes_NNS has_VBZ not_RB been_VBN completely_RB elucidated_VBN at_IN the_DT molecular_JJ level_NN ,_, it_PP could_MD be_VB hypothesized_VBN that_DT induction_NN of_IN expression_NN of_IN SAP5_NP may_MD have_VB resulted_VBN from_IN signaling_VBG events_NNS occurring_VBG in_IN response_NN to_TO cell_NN wall_NN damage_NN by_IN caspofungin_NN ._SENT The_DT C._NP albicans_NNS transcriptional_JJ regulators_NNS CPH1_NP and_CC EFG1_NP mediate_VBP the_DT activation_NN of_IN the_DT SAP5_NP gene_NN and_CC may_MD have_VB been_VBN up-regulated_JJ after_IN exposure_NN to_TO caspofungin_NN ._SENT Alternatively_RB ,_, peptide_NN hydrolysis_NN products_NNS of_IN the_DT cyclic_JJ hexapeptide_NN caspofungin_NN may_MD have_VB induced_VBN expression_NN of_IN SAP5_NP ,_, because_IN peptides_NNS up-regulate_JJ expression_NN of_IN the_DT SAP_NP genes_NNS in_IN vitro_NN ._SENT Because_IN the_DT RT-PCR_NP analysis_NN was_VBD conducted_VBN on_IN the_DT portion_NN of_IN C._NP albicans_NNS cells_NNS exposed_VBN to_TO but_CC not_RB yet_RB killed_VBN by_IN the_DT antifungal_JJ agent_NN ,_, inhibition_NN of_IN 1,3-beta-d-glucan_JJ synthesis_NN by_IN caspofungin_NN was_VBD rapidly_RB fungicidal_JJ against_IN C._NP albicans_NNS before_IN the_DT expression_NN of_IN virulence_NN genes_NNS could_MD be_VB perturbed_VBN ._SENT The_DT absence_NN of_IN suppression_NN of_IN expression_NN of_IN SAP_NP genes_NNS ,_, PLB1_NP ,_, and_CC the_DT control_NN EFB1_JJ gene_NN by_IN caspofungin_NN concurs_VBZ with_IN the_DT highly_RB specific_JJ inhibition_NN of_IN glucan_JJ synthase_NN by_IN the_DT close_JJ analogue_NN L-733,560_NP ,_, which_WDT begins_VBZ to_TO show_VB nonspecific_JJ effects_NNS at_IN 25x_NP MIC_NP ._SENT In_IN conclusion_NN ,_, it_PP is_VBZ unlikely_JJ that_IN suppression_NN of_IN SAP_NP and_CC PLB1_NP gene_NN expression_NN by_IN caspofungin_NN occurs_VBZ at_IN the_DT caspofungin_NN concentrations_NNS in_IN plasma_NN found_VBN in_IN clinical_JJ treatment_NN of_IN candidiasis_NN ,_, and_CC such_PDT an_DT indirect_JJ mechanism_NN would_MD not_RB be_VB expected_VBN to_TO contribute_VB to_TO clearance_NN of_IN C._NP albicans_NNS during_IN treatment_NN with_IN caspofungin_NN ._SENT FIG._NN 1_CD ._SENT |_SYM Plots_NP of_IN the_DT number_NN of_IN C._NP albicans_NP Plots_NP of_IN the_DT number_NN of_IN C._NP albicans_NNS treated_VBN with_IN different_JJ concentrations_NNS of_IN caspofungin_NN over_IN time_NN ._SENT The_DT mean_JJ values_NNS for_IN log10_NN of_IN the_DT number_NN of_IN CFU_NP per_IN milliliter_NN versus_CC time_NN for_IN C._NP albicans_NNS strain_VBP LAM-1_NP tested_VBD against_IN different_JJ concentrations_NNS of_IN caspofungin_NN ._SENT The_DT following_VBG concentrations_NNS (_( in_IN micrograms_NNS per_IN milliliter_NN )_) of_IN caspofungin_NN were_VBD used_VBN :_: 0_CD (_( control_NN )_) ,_, 0.0625_CD ,_, 0.125_CD ,_, 0.25_CD (_( *_SYM )_) ,_, 1_CD ,_, 4_CD ,_, 8_CD ,_, and_CC 16_CD ._SENT Caspofungin_NP was_VBD added_VBN to_TO cultures_NNS in_IN SDB_NP after_IN 15_CD h_NN of_IN incubation_NN (_( A_NP )_) or_CC at_IN the_DT start_NN of_IN culture_NN (_( B_NP )_) ._SENT Representative_NN results_NNS are_VBP shown_VBN from_IN four_CD (_( A_NP )_) and_CC two_CD (_( B_NP )_) independent_JJ experiments_NNS ._SENT FIG._NN 2_CD ._SENT |_SYM Expression_NN of_IN the_DT SAP2_NP ,_, SAP5_NP ,_, and_CC EFB1_JJ genes_NNS of_IN C._NP albicans_NNS Expression_NN of_IN the_DT SAP2_NP ,_, SAP5_NP ,_, and_CC EFB1_JJ genes_NNS of_IN C._NP albicans_NNS over_IN a_DT period_NN of_IN 7_CD h_NN after_IN the_DT addition_NN of_IN caspofungin_NN (_( 4_CD to_TO 16_CD mug/ml_NN )_) to_TO cells_NNS grown_VBN for_IN 15_CD h_NN in_IN SDB_NP ._SENT Representative_JJ results_NNS are_VBP shown_VBN from_IN two_CD independent_JJ experiments_NNS ._SENT EFB1_NP was_VBD used_VBN as_IN a_DT positive_JJ control_NN ._SENT Expression_NN of_IN the_DT remaining_VBG SAP_NP genes_NNS and_CC PLB1_NP was_VBD similar_JJ to_TO that_DT of_IN SAP2_NP ._SENT 